目次

TABLE OF CONTENTS

1. REPORT PROLOGUE

2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations

3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Product
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation

4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities

5. MARKET FACTOR ANALYSIS
5.1. Porter’s Five Forces Analysis
5.1.1. Bargaining Power of Suppliers
5.1.2. Bargaining Power of Buyers
5.1.3. Threat of New Entrants
5.1.4. Threat of Substitutes
5.1.5. Intensity of Rivalry
5.2. Value Chain Analysis
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Impact on Supply Chain
5.3.3. Regional Impact
5.3.4. Opportunity and Threat Analysis

6. GLOBAL NANO BIOTECHNOLOGYMARKET, BY APPLICATION
6.1. Overview
6.2. Pharmaceuticals
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027
6.3. Medical Devices
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027
6.4. Medical Research
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027
6.5. Food and Agriculture
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027

7. GLOBAL NANO BIOTECHNOLOGY MARKET, BY THERAPEUTICS
7.1. Overview
7.2. Dental Therapies
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027
7.3. Cardiac Therapies
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027
7.4. Orthopedic Therapies
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027
7.5. Others
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027

8. GLOBAL NANO BIOTECHNOLOGYMARKET, BY REGION
8.1. Overview
8.2. North America
8.2.1. US
8.2.2. Canada
8.3. Europe
8.3.1. Germany
8.3.2. France
8.3.3. Italy
8.3.4. Spain
8.3.5. UK
8.3.6. Rest of Europe
8.4. Asia-Pacific
8.4.1. Japan
8.4.2. China
8.4.3. India
8.4.4. Australia
8.4.5. South Korea
8.4.6. Rest of Asia-Pacific
8.5. Middle East & Africa
8.5.1. Middle East
8.5.2. Africa
8.5.3. Latin America

9. COMPANY LANDSCAPE
9.1. Overview
9.2. Competitive Analysis
9.3. Market Share Analysis
9.4. Major Growth Strategy in the Global Nano BiotechnologyMarket
9.5. Competitive Benchmarking
9.6. Leading Players in terms of Number of Developments in the Global Nano BiotechnologyMarket
9.7. Key developments and Growth Strategies
9.7.1. New ProductLaunch/Service Deployment
9.7.2. Mergers&Acquisitions
9.7.3. Joint Ventures
9.8. Major Players Financial Matrix
9.8.1. Sales & Operating Income, 2020
9.8.2. Major Players R&D Expenditure, 2020

10. COMPANY PROFILES
10.1. Ablynx
10.1.1. Company Overview
10.1.2. Products Offered
10.1.3. Financial Overview
10.1.4. Key Developments
10.1.5. SWOT Analysis
10.1.6. Key Strategies
10.2. Nami Therapeutics
10.2.1. Company Overview
10.2.2. Products Offered
10.2.3. Financial Overview
10.2.4. Key Developments
10.2.5. SWOT Analysis
10.2.6. Key Strategies
10.3. Celgene Corporation
10.3.1. Company Overview
10.3.2. Products Offered
10.3.3. Financial Overview
10.3.4. Key Developments
10.3.5. SWOT Analysis
10.3.6. Key Strategies
10.4. Nanophase Technologies Corporation
10.4.1. Company Overview
10.4.2. Products Offered
10.4.3. Financial Overview
10.4.4. Key Developments
10.4.5. SWOT Analysis
10.4.6. Key Strategies
10.5. Sigma-Aldrich
10.5.1. Company Overview
10.5.2. Products Offered
10.5.3. Financial Overview
10.5.4. Key Developments
10.5.5. SWOT Analysis
10.5.6. Key Strategies
10.6. SkyePharma Pharmaceuticals
10.6.1. Company Overview
10.6.2. Products Offered
10.6.3. Financial Overview
10.6.4. Key Developments
10.6.5. SWOT Analysis
10.6.6. Key Strategies
10.7. Nano Bridging Molecules SA
10.7.1. Company Overview
10.7.2. Products Offered
10.7.3. Financial Overview
10.7.4. Key Developments
10.7.5. SWOT Analysis
10.7.6. Key Strategies
10.8. XanTec bioanalytics GmbH
10.8.1. Company Overview
10.8.2. Products Offered
10.8.3. Financial Overview
10.8.4. Key Developments
10.8.5. SWOT Analysis
10.8.6. Key Strategies
10.9. Nanobiotix
10.9.1. Company Overview
10.9.2. Products Offered
10.9.3. Financial Overview
10.9.4. Key Developments
10.9.5. SWOT Analysis
10.9.6. Key Strategies
10.10. Dabur Pharma
10.10.1. Company Overview
10.10.2. Product Offered
10.10.3. Financial Overview
10.10.4. Key Developments
10.10.5. SWOT Analysis
10.10.6. Key Strategies

11. APPENDIX
11.1. References
11.2. Related Reports
?

LIST OF TABLES
TABLE 1 GLOBAL NANO BIOTECHNOLOGYMARKET SYNOPSIS, 2018-2027
TABLE 2 GLOBAL NANO BIOTECHNOLOGYMARKET ESTIMATES &FORECAST, 2018-2027 (USD MILLION)
TABLE 3 GLOBAL NANO BIOTECHNOLOGYMARKET, BYAPPLICATION, 2018-2027 (USD MILLION)
TABLE 4 GLOBAL NANO BIOTECHNOLOGYMARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)
TABLE 5 NORTH AMERICA NANO BIOTECHNOLOGY MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 6 NORTH AMERICA NANO BIOTECHNOLOGYMARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)
TABLE 7 US NANO BIOTECHNOLOGY MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 8 US NANO BIOTECHNOLOGYMARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)
TABLE 9 CANADA NANO BIOTECHNOLOGY MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 10 CANADA NANO BIOTECHNOLOGYMARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)
TABLE 11 EUROPE NANO BIOTECHNOLOGY MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 12 EUROPE NANO BIOTECHNOLOGYMARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)
TABLE 13 GERMANY NANO BIOTECHNOLOGY MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 14 GERMANY NANO BIOTECHNOLOGYMARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)
TABLE 15 UK NANO BIOTECHNOLOGY MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 16 UK: NANO BIOTECHNOLOGYMARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)
TABLE 17 FRANCE NANO BIOTECHNOLOGY MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 18 FRANCE NANO BIOTECHNOLOGYMARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)
TABLE 19 ITALY NANO BIOTECHNOLOGY MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 20 ITALY NANO BIOTECHNOLOGY MARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)
TABLE 21 SPAIN NANO BIOTECHNOLOGY MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 22 SPAIN NANO BIOTECHNOLOGYMARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)
TABLE 23 REST OFEUROPE NANO BIOTECHNOLOGY MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 24 REST OFEUROPE NANO BIOTECHNOLOGYMARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)
TABLE 25 ASIA-PACIFICNANO BIOTECHNOLOGY MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 26 ASIA-PACIFIC NANO BIOTECHNOLOGYMARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)
TABLE 27 INDIA NANO BIOTECHNOLOGY MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 28 INDIA NANO BIOTECHNOLOGYMARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)
TABLE 29 CHINA NANO BIOTECHNOLOGY MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 30 CHINA NANO BIOTECHNOLOGYMARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)
TABLE 31 JAPAN NANO BIOTECHNOLOGY MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 32 JAPAN NANO BIOTECHNOLOGYMARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)
TABLE 33 SOUTH KOREA NANO BIOTECHNOLOGY MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 34 SOUTH KOREA BIOTECHNOLOGY MARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)
TABLE 35 AUSTRALIA NANO BIOTECHNOLOGY MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 36 AUSTRALIA BIOTECHNOLOGY MARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)
TABLE 37 REST OF ASIA-PACIFICNANO BIOTECHNOLOGY MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 38 REST OF ASIA-PACIFIC NANO BIOTECHNOLOGYMARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)
TABLE 39 REST OF THE WORLD NANO BIOTECHNOLOGY MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 40 REST OF THE WORLD NANO BIOTECHNOLOGY MARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)
TABLE 41 MIDDLE EAST NANO BIOTECHNOLOGY MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 42 MIDDLE EAST BIOTECHNOLOGY MARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)
TABLE 43 AFRICA NANO BIOTECHNOLOGY MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 44 AFRICA NANO BIOTECHNOLOGY MARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)
TABLE 45 LATIN AMERICABIOTECHNOLOGY MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 46 LATIN AMERICANANO BIOTECHNOLOGYMARKET, THERAPEUTICS, 2018-2027 (USD MILLION)

LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL NANO BIOTECHNOLOGYMARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL NANO BIOTECHNOLOGYMARKET
FIGURE 4 GLOBAL NANO BIOTECHNOLOGY MARKET SHARE, BY APPLICATION, 2020 (%)
FIGURE 5 GLOBAL NANO BIOTECHNOLOGYMARKET SHARE, BY THERAPEUTICS, 2020 (%)
FIGURE 6 GLOBAL NANO BIOTECHNOLOGYMARKET SHARE, BY REGION, 2020 (%)
FIGURE 7 NORTH AMERICA NANO BIOTECHNOLOGYMARKET SHARE, BY REGION, 2020 (%)
FIGURE 8 EUROPE NANO BIOTECHNOLOGYMARKET SHARE, BY REGION, 2020 (%)
FIGURE 9 ASIA-PACIFIC NANO BIOTECHNOLOGYMARKET SHARE, BY REGION, 2020 (%)
FIGURE 10 REST OF THE WORLDNANO BIOTECHNOLOGYMARKET SHARE, BY REGION, 2020 (%)
FIGURE 11 GLOBAL NANO BIOTECHNOLOGYMARKET: COMPANY SHARE ANALYSIS, 2020 (%)
FIGURE 12 ABLYNX: KEY FINANCIALS
FIGURE 13 ABLYNX: SEGMENTAL REVENUE
FIGURE 14 ABLYNX: REGIONAL REVENUE
FIGURE 15 NAMI THERAPEUTICS: KEY FINANCIALS
FIGURE 16 NAMI THERAPEUTICS: SEGMENTAL REVENUE
FIGURE 17 NAMI THERAPEUTICS: REGIONAL REVENUE
FIGURE 18 CELGENE CORPORATION: KEY FINANCIALS
FIGURE 19 CELGENE CORPORATION: SEGMENTAL REVENUE
FIGURE 20 CELGENE CORPORATION: REGIONAL REVENUE
FIGURE 21 NANOPHASE TECHNOLOGIES CORPORATION: KEY FINANCIALS
FIGURE 22 NANOPHASE TECHNOLOGIES CORPORATION: SEGMENTAL REVENUE
FIGURE 23 NANOPHASE TECHNOLOGIES CORPORATION: REGIONAL REVENUE
FIGURE 24 SIGMA-ALDRICH: KEY FINANCIALS
FIGURE 25 SIGMA-ALDRICH: SEGMENTAL REVENUE
FIGURE 26 SIGMA-ALDRICH: REGIONAL REVENUE
FIGURE 27 SKYEPHARMA PHARMACEUTICALS: KEY FINANCIALS
FIGURE 28 SKYEPHARMA PHARMACEUTICALS: SEGMENTAL REVENUE
FIGURE 29 SKYEPHARMA PHARMACEUTICALS: REGIONAL REVENUE
FIGURE 30 NANO BRIDGING MOLECULES SA: KEY FINANCIALS
FIGURE 31 NANO BRIDGING MOLECULES SA: SEGMENTAL REVENUE
FIGURE 32 NANO BRIDGING MOLECULES SA: REGIONAL REVENUE
FIGURE 33 XANTEC BIOANALYTICS GMBH: KEY FINANCIALS
FIGURE 34 XANTEC BIOANALYTICS GMBH: SEGMENTAL REVENUE
FIGURE 35 XANTEC BIOANALYTICS GMBH: REGIONAL REVENUE
FIGURE 36 NANOBIOTIX: KEY FINANCIALS
FIGURE 37 NANOBIOTIX: SEGMENTAL REVENUE
FIGURE 38 NANOBIOTIX: REGIONAL REVENUE
FIGURE 39 DABUR PHARMA: KEY FINANCIALS
FIGURE 40 DABUR PHARMA: SEGMENTAL REVENUE
FIGURE 41 DABUR PHARMA: REGIONAL REVENUE